Company profile
BURZYNSKI RESEARCH INSTITUTE INC CIK 724445
Ticker
BZYR (OTC)
Industry
In Vitro & In Vivo Diagnostic Substances
Headquarters
Houston, TX 77082
Fiscal year end
2025 (FY)
Key Financials
Revenue
$0
Net income
-$1.39M
Total assets
$847
Total liabilities
$42.5K
Stockholders' equity
-$41.6K
Cash & equivalents
$847
Operating income
-$1.39M
Operating cash flow
-$388.5K
Capital expenditures
—
Fiscal year 2025, via 10-K filed 2025-05-20. A dash means this figure wasn't reported in the source filing under a field State Ledger recognizes - not that the value is zero.
Financial Performance
Operating margin
—
Net margin
—
Free cash flow
—
Free cash flow margin
—
Liabilities / assets
5,015.8%
Equity / assets
-4,915.8%
CapEx / revenue
—
Operating cash flow / net income
0.28×
Derived from the fiscal year 2025 figures above. These metrics are mathematical calculations and do not represent a rating or assessment of the company.
Financial History
Fiscal yearRevenueNet incomeAssetsLiabilitiesEquity
2025
$0
-$1.39M
$847
$42.5K
-$41.6K
2024
$0
-$1.34M
$2.3K
$27.4K
-$25.1K
2023
$0
-$916.3K
$1.9K
$15.7K
-$13.7K
2022
$0
-$976.7K
$4.7K
$3.5K
$1.2K
2021
$0
-$1.20M
$956
$46.8K
-$45.8K
Company Details
SIC code
2835
State of incorporation
DE
Active filer
Yes
Most recent SEC filing
Form 8-K
2026-05-12
Financials filed via
Form 10-K
filed 2025-05-20
"Most recent SEC filing" may differ from the filing used for the financial figures above.
Location
Houston, TX 77082
Data & Methodology
SEC EDGAR submissions API (identity, collected Sep 19, 2026, 15:11 UTC) and SEC XBRL Company Facts API (financials, collected Sep 26, 2026, 15:54 UTC) · figures as originally filed, not restated · a dash always means a value wasn't reported, never a real zero.